Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human immunodeficiency virus 1

ABSTRACT: Broad neutralizing HIV antibodies

PROVIDER: PRJNA294363 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR2241770_1.fastq.gz	Fastqsanger.gz
	SRR2241770_2.fastq.gz	Fastqsanger.gz
	SRR2241780_1.fastq.gz	Fastqsanger.gz
	SRR2241780_2.fastq.gz	Fastqsanger.gz
	SRR2241790_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 56

Similar Datasets

Human immunodeficiency virus 1

Project description:Phase-I trial of broadly neutralizing anti-HIV-1 antibody 10-1074

| PRJNA356756 | ENA

Variability in the Glycosylation Patterns of gp120 Proteins from Different Human Immunodeficiency Virus Type 1 Isolates Expressed in Different Host Cells

Project description:The mature HIV-1 envelope (Env) glycoprotein is composed of gp120, the exterior subunit, and gp41, the transmembrane subunit assembled as trimer by noncovalent interaction. There is a great body of literature to prove that gp120 binds to CD4 first, then to the co-receptor. We have recently demonstrated that gp120 cannot bind to the co-receptor without first interacting with CD4. Previous studies provided different glycomic maps for the HIV-1 gp120. Here, we build on previous work to report that the use of LC-MS/MS, in conjunction with hydrophilic interaction liquid chromatography (HILIC) enrichment to glycosylation sites, is associated with the assorted neutralizing or binding events of glycosylation targeted antibodies from different clades or strains. In this study, the microheterogeneity of the glycosylation from 4 different clades of gp120s is deeply investigated. Aberrant glycosylation patterns were detected on gp120 originated from different clades, viral sequences and host cells. The results of this study may help provide better understanding of the mechanism of how the glycans participate in antibody neutralizing process that target glycosylation sites.

2021-11-01 | PXD027353 | Pride

Human immunodeficiency virus

Project description:Comparison of HIV-1 and HIV-2 Mutagenesis by Illumina Sequencing

| PRJNA287455 | ENA

Innate protection against intrarectal SIV acquisition by a live Simian-Human immunodeficiency virus vaccine

Project description:Identifying immune correlates of protection is a major challenge in AIDS vaccine development. Anti-Envelope antibodies have been considered critical against SIV/HIV acquisition. Here, we evaluated the efficacy of a SHIV vaccine against SIVmac251 challenge, where the role of antibody was excluded as there was no cross-reactivity between SIV and SHIV Envelope antibodies. After eight low-dose rectal challenges with SIVmac251, 12 SHIV-vaccinated animals demonstrated 83% efficacy, compared to six naïve controls, suggesting protection could be achieved in the absence of anti-Envelope antibodies. Interestingly, CD8+ T cells (and some NK cells) were not essential for the preventing viral acquisition, as none of the CD8-depleted macaques were infected by SIVmac251 challenges. Initial investigation of protective innate immunity revealed that protected animals had elevated pathways related to platelet aggregation/activation, and reduced pathways related to interferon and responses to virus. Moreover, higher expression of platelet factor 4 (PF4) on circulating platelet-leukocyte aggregates was associated with reduced viral acquisition. Our data highlighted the importance of innate immunity and may provide new opportunities for novel HIV vaccines or therapeutic strategy development.

2024-09-30 | GSE242726 | GEO

Human immunodeficiency virus 1 strain:HXB2

Project description:Anti-HIV-1 CAR-T cells armed with autogenic broadly neutralizing antibody and follicle-homing receptor CXCR5 ar effective against different HIV-1 clades and reduce viral reservoir in HIV-1-infected individuals

| PRJNA903552 | ENA

Human immunodeficiency virus 1

Project description:HIV-1 genome sequencing, genetic analysis of HIV-1 recombinant forms

| PRJDB13369 | ENA

Human immunodeficiency virus 1

Project description:HIV LTR terminus sequence

| PRJDB9357 | ENA

Human immunodeficiency virus 1

Project description:HIV-1 quasispecies analysis

| PRJDB3502 | ENA

Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens

Project description:HIV-1 vaccine immunofocusing strategies have the potential to induce broadly reactive nAbs. Here, we engineered a panel of diverse, membrane-resident native HIV-1 trimers vulnerable to two broad targets of neutralizing antibodies (NAbs), the V2 apex and fusion peptide (FP). This dataset contains the raw files used to obtain site-spefific glycan analysis of the membrane-resident HIV-1 trimers

| MSV000088108 | MassIVE

Human immunodeficiency virus 1

Project description:Polymorphisms of HIV-1 integrase

| PRJDB3501 | ENA